Role of Interferon-gamma Release Assays for Screening and Monitoring of Latent Tuberculosis Infection in Kidney Transplant Recipients

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200928005

Enrollment

100

Registered

2020-09-28

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplantation Latent TB infection IGRA kidney transplantation

Interventions

Heparanized blood to check for TB&#45

specific T cell responses

Experimental Other

T&#45

spot TB assay

Eligibility

Sex/Gender

All

Age

15 Years to 80 Years

Inclusion criteria

Inclusion criteria: Kidney transplant recipients with age of 15 years or older

Exclusion criteria

Exclusion criteria: Presence of active TB at the time of inclusion. Denial for participation.

Design outcomes

Primary

Measure	Time frame
TB-specific T cell responses month 0, 1, and 9 after transplant T-spot TB assay	—

Secondary

Measure	Time frame
Latent TB infection (LTBI) 0, 1, 9 months after kidney tranplantation T-spot TB	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital, Mahidol University

jackrapong.brm@mahidol.ac.th6622011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Role of Interferon&#45;gamma Release Assays for Screening and Monitoring of Latent Tuberculosis Infection in Kidney Transplant Recipients